Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients with Metastatic Melanoma

Table 3

Radiation-absorbed doses of ¹⁸⁸Re-6D2 compared to tositumomab, ibritumomab tiuxetan, and normal organ tolerance TD 5/5 (cGy).

	Liver	Kidneys	Bone marrow	Urine bladder wall
Tositumomab 81 mCi	246	588	195	192
Ibritumomab tiuxetan 30 mCi	533	11	144	100
^188Re-6D2 40–60 mCi	130	305	17	158
^188Re-6D2 Estimated 100 mCi	344	650	42	350
Normal Organ Tolerance	3000	2300	200	6500